TABLE 1.

PATIENT DEMOGRAPHICS

	Age (yr)	Sex	FEV1 (% pred)	PD20 (SQE)	Late phase	IgE	Allergen Provocation SQ-U
Patients without cross-linked SP-D (n = 8)
	35	F	101	745	−	20	1,000
	32	M	87	1,372	+	289	1,000
	23	F	101	149	−	173	1,000
	21	F	97	1,124	−	186	100,000
	22	F	101	87	−	353	100,000
	27	M	90	268	−	233	1,000
	25	F	79	234	+	767	10,000
	29	F	94	52	+	183	1,000
Median	26		96	251		210
Range	21–35	6F/2M	79–101	52–1,372		20–767
Patients with cross-linked SP-D (n = 7)
	34	F	109	49	−	444	100
	37	M	98	90	+	246	100
	26	M	107	485	+	15	1,000
	24	F	104	9	+	495	10,000
	32	M	80	175	+	130	10,000
	31	M	111	240	−	24	100,000
	23	F	128	898	−	161	100,000
Median	31		107	175		161
Range	23–37	3F/4M	80–128	9–898		15–495

Definition of abbreviation: SP-D = surfactant protein D.

All study subjects were nonsmokers. None suffered from acute bronchitis or received treatment with corticosteroids, sodium cromoglycate, theophylline, or leucotriene modifiers within 4 weeks of bronchoscopy. Patients used β₂-agonists only when required for relief of symptoms. FEV₁ is given as percent of predicted normal. PD₂₀ provocation dose of allergen causing a 20% drop in FEV₁. Allergen sensitivity was determined by skin-prick test. Allergen provocation was done with the indicated amount (SQ-U) of Dermatophagoides pteronyssinus mix diluted in 10 ml of saline solution.